Takeda Pharmaceutical Co. is pursuing its biggest acquisition after destroying more value for shareholders than any drugmaker and hoarding the most cash.Owning Takeda has cost investors almost 40 percent of their money in the past five years, the most of any pharmaceutical company with more than $10 billion in market value, according to data compiled by Bloomberg. Over that span, the average drugmaker returned 35 percent as the Osaka, Japan-based company held onto $10.4 billion more cash than debt.
